Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 2
1946 4
1947 2
1948 6
1949 2
1950 5
1951 8
1952 3
1953 1
1954 3
1955 5
1956 2
1957 1
1958 2
1960 2
1961 1
1962 3
1963 3
1964 1
1965 1
1967 1
1968 1
1969 1
1970 1
1971 2
1972 2
1978 3
1979 5
1981 2
1982 4
1983 6
1984 6
1985 8
1986 6
1987 5
1988 10
1989 3
1990 6
1991 6
1992 5
1993 8
1994 6
1995 2
1996 4
1997 5
1998 10
1999 7
2000 11
2001 8
2002 14
2003 7
2004 8
2005 12
2006 11
2007 18
2008 15
2009 16
2010 20
2011 18
2012 19
2013 20
2014 23
2015 19
2016 26
2017 25
2018 34
2019 31
2020 37
2021 50
2022 46
2023 30
2024 36

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

670 results

Results by year

Filters applied: . Clear all
Page 1
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.
André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Bléry M, Bonnafous C, Gauthier L, Morel A, Rossi B, Remark R, Breso V, Bonnet E, Habif G, Guia S, Lalanne AI, Hoffmann C, Lantz O, Fayette J, Boyer-Chammard A, Zerbib R, Dodion P, Ghadially H, Jure-Kunkel M, Morel Y, Herbst R, Narni-Mancinelli E, Cohen RB, Vivier E. André P, et al. Among authors: morel a. Cell. 2018 Dec 13;175(7):1731-1743.e13. doi: 10.1016/j.cell.2018.10.014. Epub 2018 Nov 29. Cell. 2018. PMID: 30503213 Free PMC article. Review.
Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123.
Gauthier L, Virone-Oddos A, Beninga J, Rossi B, Nicolazzi C, Amara C, Blanchard-Alvarez A, Gourdin N, Courta J, Basset A, Agnel M, Guillot F, Grondin G, Bonnevaux H, Bauchet AL, Morel A, Morel Y, Chiron M, Vivier E. Gauthier L, et al. Among authors: morel a. Nat Biotechnol. 2023 Sep;41(9):1296-1306. doi: 10.1038/s41587-022-01626-2. Epub 2023 Jan 12. Nat Biotechnol. 2023. PMID: 36635380 Free PMC article.
Atypical Anti-Glomerular Basement Membrane Nephritis: A Case Series From the French Nephropathology Group.
Chauveau B, Gibier JB, Olagne J, Morel A, Aydin S, McAdoo SP, Viallet N, Perrochia H, Pambrun E, Royal V, Demoulin N, Kemeny JL, Philipponnet C, Hertig A, Boffa JJ, Plaisier E, Domenger C, Brochériou I, Deltombe C, Duong Van Huyen JP, Buob D, Roufosse C, Hellmark T, Audard V, Mihout F, Nasr SH, Renaudin K, Moktefi A, Rabant M; CFPR–French Nephropathology Group. Chauveau B, et al. Among authors: morel a. Am J Kidney Dis. 2024 Jun;83(6):713-728.e1. doi: 10.1053/j.ajkd.2023.11.003. Epub 2024 Jan 1. Am J Kidney Dis. 2024. PMID: 38171412
Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant.
Demaria O, Gauthier L, Vetizou M, Blanchard Alvarez A, Vagne C, Habif G, Batista L, Baron W, Belaïd N, Girard-Madoux M, Cesari C, Caratini M, Bosco F, Benac O, Lopez J, Fenis A, Galluso J, Trichard S, Carrette B, Carrette F, Maguer A, Jaubert S, Sansaloni A, Letay-Drouet R, Kosthowa C, Lovera N, Dujardin A, Chanuc F, Le Van M, Bokobza S, Jarmuzynski N, Fos C, Gourdin N, Remark R, Lechevallier E, Fakhry N, Salas S, Deville JL, Le Grand R, Bonnafous C, Vollmy L, Represa A, Carpentier S, Rossi B, Morel A, Cornen S, Perrot I, Morel Y, Vivier E. Demaria O, et al. Among authors: morel a. Cell Rep Med. 2022 Oct 18;3(10):100783. doi: 10.1016/j.xcrm.2022.100783. Cell Rep Med. 2022. PMID: 36260981 Free PMC article.
Genomics to select treatment for patients with metastatic breast cancer.
Andre F, Filleron T, Kamal M, Mosele F, Arnedos M, Dalenc F, Sablin MP, Campone M, Bonnefoi H, Lefeuvre-Plesse C, Jacot W, Coussy F, Ferrero JM, Emile G, Mouret-Reynier MA, Thery JC, Isambert N, Mege A, Barthelemy P, You B, Hajjaji N, Lacroix L, Rouleau E, Tran-Dien A, Boyault S, Attignon V, Gestraud P, Servant N, Le Tourneau C, Cherif LL, Soubeyran I, Montemurro F, Morel A, Lusque A, Jimenez M, Jacquet A, Gonçalves A, Bachelot T, Bieche I. Andre F, et al. Among authors: morel a. Nature. 2022 Oct;610(7931):343-348. doi: 10.1038/s41586-022-05068-3. Epub 2022 Sep 7. Nature. 2022. PMID: 36071165 Clinical Trial.
Cellular Plasticity: A Route to Senescence Exit and Tumorigenesis.
De Blander H, Morel AP, Senaratne AP, Ouzounova M, Puisieux A. De Blander H, et al. Among authors: morel ap. Cancers (Basel). 2021 Sep 11;13(18):4561. doi: 10.3390/cancers13184561. Cancers (Basel). 2021. PMID: 34572787 Free PMC article. Review.
A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma.
Demaria O, Habif G, Vetizou M, Gauthier L, Remark R, Chiossone L, Vagne C, Rebuffet L, Courtois R, Denis C, Le Floch F, Muller M, Girard-Madoux M, Augier S, Lopez J, Carrette B, Maguer A, Vallier JB, Grondin G, Baron W, Galluso J, Yessaad N, Giordano M, Simon L, Chanuc F, Alvarez AB, Perrot I, Bonnafous C, Represa A, Rossi B, Morel A, Morel Y, Paturel C, Vivier E. Demaria O, et al. Among authors: morel a. Sci Immunol. 2024 Nov 15;9(101):eadp3720. doi: 10.1126/sciimmunol.adp3720. Epub 2024 Nov 15. Sci Immunol. 2024. PMID: 39546590
[Lower-limb peripheral arterial disease].
Le Hello C, Fouillet L, Boulon C, Rivière S, El Jaouhari A, Seffert B, Morel A, Boissier C. Le Hello C, et al. Among authors: morel a. Rev Med Interne. 2020 Oct;41(10):667-672. doi: 10.1016/j.revmed.2020.03.009. Epub 2020 Apr 30. Rev Med Interne. 2020. PMID: 32359979 Review. French.
670 results